Aktis Oncology, Inc. (AKTS) Stock
AKTS has an Alpha Score of 22 out of 100 (poor), computed on Nov 10, 2026 from 2 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported AKTS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Soros Fund Management's at $3.22M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is AKTS's Alpha Score?
How it works →Alpha Score of 22 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own AKTS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Soros Fund Management George Soros (founder) | 100K | $3.22M | n/a |
| Renaissance Technologies Jim Simons (founder) | 95K | $3.07M | NEW |
| Citadel Ken Griffin | 26K | $823.1K | -66% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Aktis Oncology, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 23, 26 | Czibere Akos | Chief Medical Officer | SELL | 5.1K | $103K |
| Sep 23, 26 | Czibere Akos | Chief Medical Officer | SELL | 7.4K | $156K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are AKTS's key statistics?
Key statistics as of Nov 2, 2026
How does AKTS's valuation compare with the Technology sector?
| Metric | AKTS | Technology median | Companies in median |
|---|---|---|---|
| Net margin | -810.19% | 10.87% | 220 |
| Return on equity | -30.80% | 13.88% | 223 |
Medians over the Technology stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
AKTS price chart
Powered by TradingViewWhat does Aktis Oncology, Inc. do?
Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.